Acadia Investigates Nuplazid (Pimavanserin) Therapy to Treat Psychosis in Alzheimer’s Patients

Acadia Investigates Nuplazid (Pimavanserin) Therapy to Treat Psychosis in Alzheimer’s Patients
Acadia Pharmaceuticals plans to start a Phase 3 clinical program to explore the effect of Nuplazid (pimavanserin) in Alzheimer’s disease patients with psychosis. The medication was approved by the U.S. Food and Drug Administration in April 2016 to treat similar problems with Parkinson’s patients. “We’re very pleased with our strong start to 2017,” Acadia President

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *